Blog-153-Rare-side-effects-study-of-Brigatinib

Rare side effects study of BrigatinibIn 2017, #FDA approved a next generation #ALK inhibitor #Brigatinib (Brand name #ALUNBRIG, #Ariad) as a second-line therapy after the treatment from #crizotinib (Brand name #XALHORI, #Pfizer) for #ALK+ #NSLC (non-small lung cancer). Brigatinib #tablets are generally available in 30mg , 90mg and 180mg.Normally, this #medication is well-tolerated by #patients, but in around 3% of the patients, there has been reports that patients are experiencing some very rare side effects like shortness of breath within few hours of starting treatment with brigatinib.Study conducted by researchers from Columbia University and University of Colorado #Cancer Centre had offered insights into alternative treatments that would benefit more #patients with the help of Brigatinib's side effects.See More at https://bit.ly/3ddrJKR